

# **PATIENT COOLING** PRE- & IN-HOSPITAL PRACTICAL INSIGHTS



Patient data\*


- 7.030 patients without signs of circulation (206/100,000/year)
- 1.448 resuscitation attempts by the Vienna Ambulance Service
- 361 patients with sustained ROSC (25%)
- 164 (11.3%) discharged
- 126 (8.7%) with good outcome / CPC 1-2
- \* \* 2009-2010

Out of Hospital Cardiac Arrest in Vienna: Incidence and Outcome. Nürnberger et al. Resuscitation 2013





# **VIENNA – A SHORT STORY OF COOLING**





# **VIENNA RESUSCITATION APPROACH**



PREHOSPITAL COOLING






### **EMCOOLS FLEX.PAD** HYPOCARBON <sup>®</sup>




- \* Cooling rates of up to 3.3°C/h
- \* Biocompatible material (skin- and environmentally friendly, non-toxic)



# **EMCOOLS FLEX.PAD**

CONTINUOUS COOLING CHAIN





### **EMCOOLS FLEX.PAD** PREPARATION

Preparation

- \* Remove transportation- and storage box
- In Freeze Flex.Pad<sup>™</sup> at -8 to -11°C horizontally
- Note: This temperature range reflects a pre-cooling phase of 48h (during first-time freezing)


### 2) Operational readiness

- Ready to use pads are indicated by a blue color indicator label
- \* If the pad is too cold the label turns black

#### Application

- \* Take out ready to use Flex.Pad<sup>™</sup> (blue color indicator label)
- $\ast$  Open packaging, remove protective foil and apply immediately on dry skin
- \* **Note:** For activating the adhesive press down
  - evenly for 3-5 seconds










Х



INITIAL SITUATION - OUT-OF-HOSPITAL CARDIAC ARREST

### **PRE-HOSPITAL TREATMENT** (1/30/2015)

- \* 16:25 69 year old male, loses consciousness in public bus
- \* 16:26 Emergency call & start bystander basic life support
- \* 16:33 Arrival of Vienna Ambulance Service & advanced cardiac life support
  - $\rightarrow$  Ventricular fibrillation as initial rhythm
  - $\rightarrow$  6 mg epinephrine , 300 mg amiodarone
  - $\rightarrow$  6 defibrillations
- \* 16:46 → ROSC
- \* Application of Flex.Pad at an initial temperature of 35.3°C





**EMCOOLS** 

EASY

#### © EMCOOLS

# **PRE-HOSPITAL START WITH FLEX.PAD**


### 1. Sedation, analgesia and paralysis

- \* Midazolam 10 mg
- \* Fentanyl 0.1 mg
- \* Atracurium 25 mg
- \* Bolus administered every 30 min

# 2. Continuous temperature monitoringEsophageal temperature probe (inserted by a tubus)

**3.** Can be used on top of defibrillator pads








### APPLICATION

### Flex.Pads are applied by the first responders

- \* 1 pad on the chest (not on female breast tissue)
- \* 2 pad on the back
- \* 1 pad on the abdomen
- \* 1 pad per tigh
- $\rightarrow$  The application procedure takes about 8 minutes

### **Rule-of-thumb**

\* 1 Flex.Pad per 10 kg body weight



#### Notes


- \* Don't apply on face, toes, fingers, genital region, female breast tissue or pregnant
- \* Don't apply in case of skin diseases, inflammation, burns or any other skin injuries
- \* During treatment skin temperature does not drop below 4 to 8°C





### **PRE-HOSPITAL COOLING** CLINICAL DATA

15 patients after cardiac arrest



0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 Out-of-hospital surface cooling to induce mild hypothermia in human candia quarifyest. Uray et al. Resuscitation 2008.

EMCOOLS

INITIAL SITUATION - OUT-OF-HOSPITAL CARDIAC ARREST





30. Jan. 2015 18:05:00

25mm/s 10mm/mU ADS

50Hz

25mm/s 10mm/mU ADS

30. Jan. 2015 18:05:00

IN-HOSPITAL CONTINUATION / CATH LAB

**CATH LAB** (1/30/2015)

- \* 17:16 Arrival at Cath Lab (Cardiology, Hanusch Hospital)
- \* PTCA and two stents into circumflex artery

→ All Flex.Pads are to be removed at 34°C

 $\rightarrow$  Temperature on arrival: 33.8°C  $\rightarrow$  Initial phase already completed


**EMCOOLS** 

EASY EFFICIENT

CATH LAB – ANGIOGRAPHY DURING COOLING

 $\rightarrow$  Pads are radiolucent

\* Good data on safety and feasibity of cooling during angiography, X-Ray, CT, and MRI



**EMCOOLS** 

EASY EFFICIENT PATIENT

IN-HOSPITAL CONTINUATION / CARDIAC CARE UNIT

### **CARDIAC CARE UNIT** (1/30/2015)

- \* 18:05 Arrival at the CCU
- $\rightarrow$  Maintenance and rewarming

### **Therapeutic Hypothermia at 33°±1°C for 24 hours** (1/30/2015 – 1/31/2015)

- Continuous temperature monitoring by esophageal and bladder temperature probes (used simultaneously)
- \* Continuous administration of analgo-sedation and paralytics (standard medication)

**EMCOOLS** 

EFFICIENT

IN-HOSPITAL CONTINUATION / CARDIAC CARE UNIT

### Maintenance at 33-34°C

\* 2 Flex.Pad reapplied twice to maintain the targeted temperature range

#### **Passive Rewarming to 37°C**


- \* Patient only covered by a regular blanket
- \* Target is rewarming to 37°C in about 8 hours, at a rewarming rate of 0.4°C/h
- \* At 37.0°C all medication is stopped

**EMCOOLS** 

EASY

IN-HOSPITAL CONTINUATION / CARDIAC CARE UNIT

#### Maintenance and Rewarming (1/31/2015)



EMCOOLS

IN-HOSPITAL CONTINUATION / CARDIAC CARE UNIT

**CCU** (1/31/2015 - 2/02/2015)

### Normothermia

\* 37.0°C for day two and three (until 72 hours after cardiac arrest)


#### **Fever control**

- \* Paracetamol, Novalgin
- \* EMCOOLS Flex.Pad<sup>™</sup> or other form of active temperature control

**EMCOOLS** 

EASY

IN-HOSPITAL CONTINUATION / CARDIAC CARE UNIT



**EMCOOLS** 

EASY EFFICIENT PATIENT COOLING

EXAMINATIONS & FURTHER TREATMENT OF SEPSIS / PNEUMONIA

### **CCU** 2/04/2015

### **Chest x-ray**

- \* Unremarkable, but putrid secretions from suctioning
- \* Started Amoxi/Clav, changed to Moxifloxacillin, finally Merpoenem/Linezolid
- \* Tracheal secretions
- \* Pseudomonas aeruginosa,
- \* Citrobacter freundii
- → Pneumonia and sepsis



**EMCOOLS** 

EASY EFFICIENT

SIDE EFFECTS - RISK OF INFECTION



### Therapeutic Hypothermia and the Risk of Infection:

\* A Systematic Review and Meta-Analysis; Geurts et al, CCM 2013

### **Objectives**

\* Systematic review and meta-analysis of randomized trials to examine the risk of infections in patients treated with hypothermia

### Results

- \* 23 studies, 2820 patients, 1396 cooled patients
- \* Cooling for several hours-days (prodecures, cardiac arrest, TBI, stroke)

### THERAPEUTIC HYPOTHERMIA SIDE EFFECTS - RISK OF INFECTION



#### **Findings**

All infections: no increased risk

**Risk of pneumonia** ↑ (risk ratio 1.44 [95% CI, 1.10–1.90])

**Risk of sepsis** ↑ (risk ratio 1.80 [95% CI, 1.04–3.10])

Overall prevalence of sepsis was low.

	Hypothe	rmia	Cont	lo		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Pneumonia								
Shiozaki 1993	6	9	9	13	7.9%	0.96 [0.54, 1.73]	1993	
Clifton 1993	9	24	7	22	5.2%	1.18 [0.53, 2.62]		
Shiozaki 1999	5	8	1	8	1.1%	5.00 [0.74, 33.78]		
Hindman 1999	1	53	3	56	0.8%	0.35 [0.04, 3.28]		
Jiang 2000	16	43	14	44	8.0%	1.17 [0.65, 2.09]		
Shiozaki 2001	21	43	6	40	5.2%	3.26 [1.46, 7.24]		
HACA 2002	50	135	40	137	13.5%	1.27 [0.90, 1.78]		
Hashiguchi 2003	5	9	0	8	0.6%	9.90 [0.63, 155.08]		
De Georgia 2004	2	18	1	21	0.8%	2.33 [0.23, 23.66]		
Todd 2005	7	499	7	502	3.4%	1.01 [0.36, 2.85]		
Liu 2006	8	21	8	23	5.3%	1.10 [0.50, 2.39]		
Qiu 2007	23	40	13	40	9.1%	1.77 [1.05, 2.98]		
Weber 2008	2	22	4	22	1.6%	0.50 [0.10, 2.45]		
Lee 2010	4	15	4	16	2.7%	1.07 [0.32, 3.52]		
Gotberg 2010	3	9	0	9	0.5%	7.00 [0.41, 118.69]		
Hemmen 2010	14	28	3	30	2.9%	5.00 [1.61, 15.57]		
Subtotal (95% CI)	A.C.M	976		991	68.7%	1.44 [1.10, 1.90]		•
Total events	176		120					
Heterogeneity: Tau <sup>2</sup> =	0.08; Chi <sup>a</sup>	= 22.0	9, df = 15	(P = 0.	11); I= 3	2%		
Test for overall effect								
Urinary tract i	nfection							
Jiang 2000	16	43	15	44	8.3%	1.09 [0.62, 1.92]	2000	
De Georgia 2004	1	18	4	21	0.9%	0.29 [0.04, 2.38]	2004	
Todd 2005	15	499	18	502	6.6%	0.84 [0.43, 1.64]	2005	
Weber 2008	0	22	4	22	0.5%	0.11 [0.01, 1.95]	2008	+
Lee 2010	3	15	4	16	2.2%	0.80 [0.21, 3.00]		
Stone 2011	1	58	3	70	0.8%	0.40 [0.04, 3.76]	2011	
Subtotal (95% CI)		655		675	19.4%	0.86 [0.58, 1.28]		•
Total events	36		48					
Heterogeneity: Tau <sup>2</sup> :	= 0.00; Chi <sup>a</sup>	= 4.37	df = 5 (P	= 0.50	); 1= 0%			
Test for overall effect	Z = 0.75 (F	P = 0.45	5)					
Sepsis								
Clifton 1993	9	24	4	22	3.5%	2.06 [0.74, 5.75]	1993	
HACA 2002	17	135	9	138	5.4%	1.93 [0.89, 4.18]	2002	
Todd 2005	5	499	3	502	1.9%	1.68 [0.40, 6.98]	2005	
Els 2006	0	12	0	13		Not estimable	2006	
Lee 2010	1	15	1	16	0.6%	1.07 [0.07, 15.57]	2010	
Stone 2011	0	58	1	70	0.4%	0.40 [0.02, 9.66]	2011	
Subtotal (95% CI)		743		761	11.9%	1.80 [1.04, 3.10]		-
Total events	32		18					
Heterogeneity: Tau <sup>2</sup> = Test for overall effect				= 0.89	); l² = 0%			
Total (95% CI)		2374		2427	100.0%	1.31 [1.07, 1.62]		•
Total events	244		186					
Heterogeneity: Tau <sup>2</sup> = Test for overall effect	Z = 2.56 (F		8, df = 26 )			1%		0.01 0.1 10 100 Hypothermia decreases Hypothermia increases

© EMCOOLS

### THERAPEUTIC HYPOTHERMIA SIDE EFFECTS - RISK OF INFECTION



### Conclusio

- \* Lack of definition of infections
- \* Assessment of infections not blinded
- \* Only one cardiac arrest study included
- \* Take-home-message: high alertness towards signs of infection

### PROPHYLACTIC ANTIBIOTICS?



Prophylactic antibiotics are associated with a lower incidence of pneumonia in cardiac arrest survivors treated with targeted temperature management  $^{\ddagger}$ 

David J. Gagnon<sup>a,e,\*</sup>, Niklas Nielsen<sup>b,e</sup>, Gilles L. Fraser<sup>a,c,e</sup>, Richard R. Riker<sup>c,d,e</sup>, John Dziodzio<sup>c,e</sup>, Kjetil Sunde<sup>e,f</sup>, Jan Hovdenes<sup>e,g</sup>, Pascal Stammet<sup>e,h</sup>, Hans Friberg<sup>e,i</sup>, Sten Rubertsson<sup>e,j</sup>, Michael Wanscher<sup>e,k</sup>, David B. Seder<sup>c,d,e</sup>

Univariate analysis of outcomes related to prophylactic antibiotics.

Variable	All Patients ( <i>n</i> = 1240)	PRO ( <i>n</i> = 416)	No-PRO ( <i>n</i> = 824)	pa
Serious infections, <i>n</i> (%) <sup>b</sup>	( <i>n</i> = 1206)	(n = 414)	( <i>n</i> = 792)	
Any serious infection	553 (45.9%)	67 (16.2%)	486 (61.4%)	<0.001
Pneumonia	487 (40.4%)	52 (12.6%)	435 (54.9%)	<0.001
Sepsis	50 (4.1%)	5 (1.2%)	45 (5.7%)	<0.001
Other	57 (4.7%)	13 (3.1%)	44 (5.6%)	0.06
None	653 (54.1%)	347 (83.8%)	306 (38.6%)	< 0.001

#### Conclusio

Prophylactic antibiotics were associated with a reduced incidence of pneumonia Functional outcome was similar

### RESUSCITATION, IN PRESS



NEUROLOGIC RECOVERY

**CCU** (02/03/2015)

- \* Patient regained consciousness
- \* Patient is extubated on 02/06/2015

Time on CCU: 01/30-02/11/2015 Regular Ward: 02/11-02/20/2015

 $\rightarrow$  No neurologic sequelae (OPC 1, CPC 1)

### SEDATION



### Sedation Standard - Department for Emergency Medicine, Medical Univ. Vienna

- \* Midazolam 0,125 mg/kg/h
- \* Fentanyl 0,002 mg/kg/h
- \* Esmeron 0,25 mg/kg/h

### **Hypothermia and Drugs**

- \* Affects drug metabolism
- \* Affects drug/receptor interaction
- \* During hypothermia: high blood levels, reduced effect
- \* During rewarming: toxicity develops





### Comparison of midazolam/ fentanyl versus propofol/remifentanil

- \* Randomized clinical study comparing, 50 Patients
- \* Lower time to offset for propofol/remifentanil 13.2 (2.3–24) vs. 36.8 (28.5–45.1)
- \* Norepinephrine infusion needed twice as often
- \* Same outcome

### \* Free full text review:

\* Zhou and Poloyac

The effect of therapeutic hypothermia on drug metabolism and drug response: cellular mechanisms to organ function

\* Expert Opin Drug Metab Toxicol. 2011 July ; 7(7): 803–816.


\* longer collapse to ROSC interval in the No-MB-group

NEUROMUSCULAR BLOCKADE

\* improved lactate clearance

\* Better survival

**Some problems** 



Salciccioli et al. Continuous neuromuscular blockade is associated with decreased mortality in post-cardiac arrest patients. Resuscitation 2013.


#### © EMCOOLS

**EMCOOLS** EASY EFFICIENT PATIENT

### **THERAPEUTIC HYPOTHERMIA** EFFECT ON OUTCOME – VF PATIENTS, HACA-STUDY




### First randomized trials (2002)



© EMCOOLS


### THERAPEUTIC HYPOTHERMIA HACA-STUDY





### 33°C vs. 36°C

### How cool is cool enough?






EMCOOLS

The NEW ENGLAND JOURNAL of MEDICINE


#### ORIGINAL ARTICLE


Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest



### 33°C vs. 36°C

How close do you want your brain to the heat?





### 33°C vs. 36°C



### How close do you want your brain to be to the heat?




Figure 1. Mean temperature recordings for all patients. *Horizontal bars* mark the target temperature range of  $32-34^{\circ}$ C. Time 0 represents cooling initiation (n = 32).

Merchant et al, CCM 2006: Therapeutic hypothermia after cardiac arrest: Unintentional overcooling is common using ice packs and conventional cooling blankets



### **ONGOING STUDIES IN:**

- Cooling during CPR
- Stroke
- MI
- Traumatic brain injury
- Spinal chord injury
- Hepatic encephalopathy
- Heat stroke



# Thank you!

March 2015